Ampicillin Market Size Worth US$ 238.29 billion by 2031 | Growth Plus Reports
Growth Plus Reports
6 min read
Growth Plus Reports
Newark, New Castle, USA, April 24, 2023 (GLOBE NEWSWIRE) -- The global Ampicillin Market, estimated at US$ 177.91 million in 2022, is projected to surpass US$ 238.29 billion by 2031, at a revenue CAGR of 3.30%, according to the latest evaluation by Growth Plus Reports. The study examines the best impactful strategies, macroeconomic conditions, trends and prospects, competitive environments, changing market dynamics, market size, data and projections, and key investment areas.
Key Takeaways:
The increasing prevalence of bacterial infections will drive the demand for ampicillin during the forecast period.
Increasing demand for ampicillin drugs will encourage market revenue growth.
Indications, Route of Administration, Distribution Channel, and Region
Regional Scope
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Market Drivers The rising prevalence of bacterial infections such as respiratory tract infections, urinary tract infections, skin, and soft tissue infections are the primary factors driving the revenue growth of the global ampicillin market. Additionally, increasing government healthcare spending, a stronger emphasis on infection control methods, the proper use of antibiotics, a higher demand for ampicillin drugs to treat bacterial infections in the elderly and immunocompromised people contribute to market revenue growth.
Market Segmentation Growth Plus Reports has analyzed the global ampicillin market from four perspectives: Indications, Route of Administration, Distribution Channel, and Region.
Indications Segmentation: Based on the indications, the global ampicillin market is segmented into meningitis, respiratory tract infections, urinary tract infections, gastrointestinal infections, and others. The respiratory tract infections segment dominates the market with the largest revenue share because of the high prevalence of respiratory tract infections globally.
Route of Administration Segmentation: Based on the route of administration, the global ampicillin market is segmented into oral and parenteral. The oral segment dominates the market because of the convenience and availability of oral preparations, which patients prefer.
Distribution Channel Segmentation: Based on the distribution channel, the global ampicillin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution channel. The hospital pharmacy segment dominates the market because Ampicillin is widely used in hospitals to treat a variety of bacterial infections, and competent healthcare personnel are readily available to give the medicine.
Regional Growth Dynamics Based on the region, the global ampicillin market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominates the global ampicillin market with the largest revenue share. The considerable revenue share of North America in the global ampicillin market can be attributed to the region's high frequency of bacterial diseases, the existence of large pharmaceutical firms, and growing public awareness of the advantages of early detection and treatment of bacterial infections.
The following are the top companies in the global ampicillin market:
Pfizer, Inc.
Zydus Cadila Healthcare Ltd.
Sanofi Aventis Pharma India
Teva Pharmaceuticals
Merck & Co.
Wockhardt Ltd.
Lyka Hetero Labs
Jagsonpal Pharmaceuticals Limited
ACS Dobfar S.p.A.
Viatris Inc.
The market for ampicillin is very competitive and complex. Prominent companies are developing new products and forming strategic alliances to successfully fulfill the growing global demand and maintain a strong market position.
Recent developments:
The Infectious Diseases Society of America recommended amoxicillin, ampicillin, and aminopenicillin (AP) medications for the treatment of enterococcus UTIs in January 2023. Penicillin antibiotics kill Enterococcus species and ampicillin-resistant Enterococcus isolated from lower urinary tract infections.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL AMPICILLIN MARKET - ANALYSIS & FORECAST, BY INDICATIONS
Meningitis
Respiratory Tract Infections
Urinary Tract Infections
Gastrointestinal Infections
Others
GLOBAL AMPICILLIN MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
Oral
Parenteral
GLOBAL AMPICILLIN MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
Fibrous Dysplasia Market by Type (Monostotic Fibrous Dysplasia, Polyostotic Fibrous Dysplasia), Treatment (Surgery and Medication) – Global Outlook & Forecast 2023-2031
Stuttering Therapeutics Market by Type (Developmental Stuttering, Neurogenic Stuttering), Treatment (Cognitive Behavioral Therapy, Speech Therapy), End User (Hospitals, Specialty Clinics) - Global Outlook and Forecast 2023-2031
Catheter Introducer Sheaths Market by Product (Integrated Introducer Sheaths and Separable Introducer Sheaths), Application (Cardiology, Vascular), End User (Hospitals, Ambulatory Surgery Centers) - Global Outlook and Forecast 2023-2031
Medical Nitroglycerin Sprays Market by Application (Prophylaxis of Angina Pectoris, Acute Relief of Attack), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Outlook and Forecast 2023-2031
Mastopexy Market by Technique (Benelli Lift, Crescent Breast Lift), End User (Specialty Clinics, Hospitals) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
